..
A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org
-- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
============================================================

Saturday, November 5, 2011
Avanir enrolls first patient in Prime study for Neuropathic pain
..
The Multiple Sclerosis Society-UK, says cancer should not receive special funding
The Multiple Sclerosis Society-UK, says cancer should not receive special funding as it takes resources away from other diseases.
READ MORE
Study Finds Signs of Progression to Clinically Definite MS
CLICK to read more
MRI Predicts Response After Starting MS Treatment
CONTINUE READING
Friday, November 4, 2011
Oral Laquinimod Unfortunately on hold
Source: Pharma Times
Thursday, November 3, 2011
MS Patients Perceive Copaxone Efficacy
Click to continue with this read